Mosunetuzumab for follicular lymphoma that came back quickly
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent for the study.
- You have follicular lymphoma grade 1 to 3a, and it has either relapsed or progressed within 24 months of starting first treatment, or did not respond to first treatment as defined by the study.
- You must have had exactly one prior treatment line of whole-body (systemic) therapy, not two or more.
- You have at least one measurable lymphoma area on scans, with a longest diameter over 15 mm (about 1.5 cm).
- Your general strength is good enough for treatment (WHO performance status 0 to 2), unless reduced mainly because the lymphoma is causing it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Mosunetuzumab for people with follicular lymphoma that has come back or stopped responding after at least two previous treatments. It is available through a compassionate use program for those who have no other options.
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
This trial tests a combination of two drugs, Mosunetuzumab and Tislelizumab, for people with relapsed or refractory follicular lymphoma. The goal is to see if this combination can help when at least two prior treatments have stopped working.
This trial tests a combination of two targeted drugs, mosunetuzumab and zanubrutinib, for people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Hear when a new Lymphoma, Follicular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.